JP2019519587A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519587A5
JP2019519587A5 JP2018568810A JP2018568810A JP2019519587A5 JP 2019519587 A5 JP2019519587 A5 JP 2019519587A5 JP 2018568810 A JP2018568810 A JP 2018568810A JP 2018568810 A JP2018568810 A JP 2018568810A JP 2019519587 A5 JP2019519587 A5 JP 2019519587A5
Authority
JP
Japan
Prior art keywords
compound
disorders
formula
pharmaceutically acceptable
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018568810A
Other languages
English (en)
Japanese (ja)
Other versions
JP6966486B2 (ja
JP2019519587A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/041199 external-priority patent/WO2018009867A1/en
Publication of JP2019519587A publication Critical patent/JP2019519587A/ja
Publication of JP2019519587A5 publication Critical patent/JP2019519587A5/ja
Priority to JP2021132225A priority Critical patent/JP2021175761A/ja
Application granted granted Critical
Publication of JP6966486B2 publication Critical patent/JP6966486B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018568810A 2016-07-07 2017-07-07 オキシステロールおよびその使用方法 Active JP6966486B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021132225A JP2021175761A (ja) 2016-07-07 2021-08-16 オキシステロールおよびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359532P 2016-07-07 2016-07-07
US62/359,532 2016-07-07
PCT/US2017/041199 WO2018009867A1 (en) 2016-07-07 2017-07-07 Oxysterols and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021132225A Division JP2021175761A (ja) 2016-07-07 2021-08-16 オキシステロールおよびその使用方法

Publications (3)

Publication Number Publication Date
JP2019519587A JP2019519587A (ja) 2019-07-11
JP2019519587A5 true JP2019519587A5 (enExample) 2020-08-13
JP6966486B2 JP6966486B2 (ja) 2021-11-17

Family

ID=59383635

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018568810A Active JP6966486B2 (ja) 2016-07-07 2017-07-07 オキシステロールおよびその使用方法
JP2021132225A Withdrawn JP2021175761A (ja) 2016-07-07 2021-08-16 オキシステロールおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021132225A Withdrawn JP2021175761A (ja) 2016-07-07 2021-08-16 オキシステロールおよびその使用方法

Country Status (19)

Country Link
US (2) US10781231B2 (enExample)
EP (2) EP3919502A1 (enExample)
JP (2) JP6966486B2 (enExample)
AU (3) AU2017292870B2 (enExample)
CY (1) CY1124631T1 (enExample)
DK (1) DK3481846T3 (enExample)
ES (1) ES2884071T3 (enExample)
HR (1) HRP20211272T8 (enExample)
HU (1) HUE055263T2 (enExample)
LT (1) LT3481846T (enExample)
MA (1) MA45598B1 (enExample)
MD (1) MD3481846T2 (enExample)
PL (1) PL3481846T3 (enExample)
PT (1) PT3481846T (enExample)
RS (1) RS62222B1 (enExample)
SI (1) SI3481846T1 (enExample)
SM (1) SMT202100468T1 (enExample)
TW (1) TWI752976B (enExample)
WO (1) WO2018009867A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI2753632T3 (fi) 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
MX390271B (es) 2015-07-06 2025-03-20 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos
FI3828194T3 (fi) 2015-07-06 2025-07-17 Sage Therapeutics Inc Oxysteroleita ja menetelmiä niiden käyttämiseksi
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
LT3481846T (lt) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
JP7149266B2 (ja) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法
IL293231B2 (en) 2016-10-18 2025-10-01 Sage Therapeutics Inc Oxysterols and methods of use thereof
MA46566A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN111777654B (zh) * 2020-06-11 2021-08-10 浙江神洲药业有限公司 一种泼尼松的制备方法
AU2022291395A1 (en) 2021-06-11 2024-01-04 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
CN115057906B (zh) * 2022-07-28 2022-12-02 中节能万润股份有限公司 利用去氢表雄酮合成胆固醇的方法

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US2673206A (en) 1950-06-07 1954-03-23 Schering Corp 25-ethinyl steroids
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
JPS5324071B2 (enExample) 1974-04-30 1978-07-18
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en) 1975-10-10 1982-03-31 Hoffmann La Roche Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja) 1976-12-28 1983-09-08 帝人株式会社 ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
JPS54163565A (en) 1978-06-09 1979-12-26 Teijin Ltd 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en) 1978-08-01 1979-11-13 Kaiser Emil T Synthesis of steroids
US4269777A (en) 1979-05-21 1981-05-26 Wisconsin Alumni Research Foundation Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en) 1980-08-13 1982-02-26 Teijin Ltd 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
JPS61254599A (ja) 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
ATE45347T1 (de) 1985-05-30 1989-08-15 Taisho Pharmaceutical Co Ltd Vitamin d3-derivate.
JPS62187485A (ja) 1986-02-13 1987-08-15 Teijin Ltd ２４，２５−エポキシコレステロ−ル類の製造法
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU698834B2 (en) 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE4338316A1 (de) 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DK0752860T3 (da) 1994-02-14 2000-11-13 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
EP1288220A3 (en) 1995-06-06 2004-07-21 Euro-Celtique Neuroactive 3.alpha.-hydroxy-steroids of the androstane and pregnane series
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
PL185622B1 (pl) 1995-06-23 2003-06-30 Novo Nordisk As Zastosowanie związku steroidowego i sposób regulacji mejozy w komórce rozrodczej ssaka
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
EP0840612A1 (en) * 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
AU3068497A (en) 1996-05-06 1997-11-26 Bionumerik Pharmaceuticals, Inc. Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja) 1996-06-10 1997-12-22 Teijin Ltd ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6122371A (en) 1997-07-22 2000-09-19 Atwell; Ronald C. Apparatus for protecting coin-operated telephones from vandalism and larceny
WO1999058497A1 (en) 1998-05-11 1999-11-18 Novo Nordisk A/S Substituted guanidines and diaminonitroethenes, their preparation and use
IL139241A0 (en) 1998-05-13 2001-11-25 Novo Nordisk As Meiosis regulating compounds
US8541600B2 (en) 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
CN1111167C (zh) 1999-10-22 2003-06-11 中国科学院上海有机化学研究所 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh) 1999-11-12 2003-01-08 中国科学院上海有机化学研究所 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
CA2466033A1 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
WO2003049685A2 (en) 2001-12-07 2003-06-19 The Regents Of The University Of California Treatment for age-related macular degeneration
PL213697B1 (pl) 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
CN102727501A (zh) 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
AU2003288231A1 (en) 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
WO2008057468A1 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
CA2691379C (en) 2007-06-20 2015-06-09 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009059961A2 (en) 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
CN101951915A (zh) 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
BRPI0912362A2 (pt) 2008-05-09 2015-10-06 Univ Emory antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
CN102482315A (zh) 2009-07-29 2012-05-30 芝加哥大学 肝x受体激动剂
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (en) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
WO2012142039A1 (en) 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
US20140335050A1 (en) 2011-05-27 2014-11-13 The General Hospital Corporation Methods, compositions, and kits for the treatment of cancer
CA2843436A1 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors
FI2753632T3 (fi) * 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
CA3152410A1 (en) 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
EP2841067A4 (en) 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
US20140149272A1 (en) 2012-08-17 2014-05-29 Trueex Group Llc Interoffice bank offered rate financial product and implementation
TR201808616T4 (tr) 2012-12-18 2018-07-23 Sage Therapeutics Inc Nöroaktif 19-alkoksi-17-ikameli steroidler, bunların ön ilaçları ve bunları kullanan tedavi yöntemleri.
US20150376225A1 (en) 2013-01-23 2015-12-31 Sphaera Pharma Pvtd. Ltd. Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
RU2021111681A (ru) 2013-03-13 2021-05-11 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, композиции и их применение
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
WO2016007762A1 (en) 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
EP3204011A4 (en) 2014-10-07 2018-06-20 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
MA42409A (fr) 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
FI3828194T3 (fi) 2015-07-06 2025-07-17 Sage Therapeutics Inc Oxysteroleita ja menetelmiä niiden käyttämiseksi
MX390271B (es) 2015-07-06 2025-03-20 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
LT3481846T (lt) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
JP7149266B2 (ja) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法
MA46566A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
IL293231B2 (en) 2016-10-18 2025-10-01 Sage Therapeutics Inc Oxysterols and methods of use thereof
ES3020935T3 (en) 2017-03-15 2025-05-23 Modernatx Inc Lipid nanoparticle formulation
KR20250109791A (ko) 2017-06-23 2025-07-17 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
US20190160078A1 (en) 2017-11-10 2019-05-30 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disorders

Similar Documents

Publication Publication Date Title
JP2018519329A5 (enExample)
JP2018519328A5 (enExample)
JP2019532079A5 (enExample)
JP2018519351A5 (enExample)
JP2017518323A5 (enExample)
JP2016518437A5 (enExample)
JP2016517851A5 (enExample)
JP2017531020A5 (enExample)
RU2018104278A (ru) Оксистеролы и способы их применения
JP2016513663A5 (enExample)
JP2015531773A5 (enExample)
JP2019524883A5 (enExample)
RU2020131091A (ru) Композиции и способы для лечения расстройств цнс
JP2010524932A5 (enExample)
JP2019535723A5 (enExample)
JP2017533968A5 (enExample)
TN2009000524A1 (en) Novel dicarboxylic acid derivatives as s1p1 receptor agonists
JP2013542261A5 (enExample)
JP2015504081A5 (enExample)
JP2018537535A5 (enExample)
JP2012502111A5 (enExample)
MX380516B (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico
JP2018538273A5 (enExample)
RU2018113718A (ru) Новые соединения
CA3015494C (en) Novel compositions and therapeutic methods